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Appropriate reference intervals of serum insulin-like growth factor I (IGF-I) is important for diagnosing and monitoring patients with 
growth hormone-related diseases. To establish reference intervals, adult individuals (n=1,334, 680 men and 654 women) were di-
vided into six age groups (20–29, 30–39, 40–49, 50–59, 60–69, ≥70). Serum IGF-I was measured by chemiluminescence immuno-
assay (Liaison). Concordance of patient classification based on reference intervals, manufacturer’s intervals, and standard deviation 
score (SDS) was evaluated. New reference intervals had higher upper and lower limits than those specified by the manufacturer. The 
agreement between classification using new reference interval and the manufacturer’s reference interval, and that using new refer-
ence interval and SDS was 75.0% (weighted kappa, 0.17), 91.9% (weighted kappa, 0.51) in men and 91.0% (weighted kappa, 0.41), 
92.5% (weighted kappa, 0.53) in women, respectively. Reference intervals should be established not only based on age and sex, but 
also on ethnicity and assay method.
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INTRODUCTION
The level of insulin-like growth factor I (IGF-I) is affected by 
various factors such as age, sex, systemic illness, ethnicity, and 
the type of the analytical method [1,2]. Therefore, reference in-
tervals of IGF-I considering those factors are necessary for the 
interpretation of measurement values in a given population. 
A few studies have been conducted among Asian populations. 
Hyun et al. [3] and Choi et al. [4] measured IGF-I and insulin-
like growth factor-binding protein 3 (IGFBP-3) levels using im-
munoradiometric assays in Korean population; however, this 
assay is not commonly used owing to the generation of radio-
isotope waste. Zhu et al. [5] recently published reference inter-
vals for IGF-I in healthy Chinese adults using a chemilumines-
cence immunoassay (Immulite 2000, Siemens Healthcare Diag-
nostics, Gwynedd, UK). However, this study enrolled insuffi-
cient numbers of subjects in each group to set the reference in-
tervals [6]. Therefore, it is necessary to establish reference inter-
vals for IGF-I based on assay methods by including a sufficient 
number of subjects in each age group, especially for the Asian 
population.
Here, we measured IGF-I levels using a chemiluminescence 
immunoassay (Liaison XL, DiaSorin S.p.A., Saluggia, Italy) 
and established reference intervals to improve the accuracy of 
diagnosis and treatment monitoring.  
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METHODS
Information regarding 5,010 patients (2,079 men, 2,931 women) 
who visited outpatient clinics (Plastic Surgery, Orthopedics, Oph-
thalmology, Dermatology, Family Medicine, Dentistry, Otorhi-
nolaryngology, Allergy and Immunology) from December 2018 
to July 2019 was reviewed, and excluded based on the following 
exclusion criteria: (1) a medical history of liver diseases, renal 
diseases, cancer, diabetes mellitus, cardiac disorder, pulmonary 
disorder, or thyroid disorder or alanine aminotransferase >54 
IU/L, aspartate aminotransferase >32 IU/L, estimated glomeru-
lar filtration rate <60 mL/min/1.73 m2, glucose ≥126 mg/dL, 
or C-reactive protein >10 mg/L; (2) no test results for liver en-
zyme, glucose, and creatinine; (3) the use of estrogen medication; 
and (4) ethnicity other than Korean. We defined “healthy” sub-
jects to be those who passed all the exclusion criteria. After ex-
clusion, a total of 1,358 subjects (688 men and 670 women) were 
selected. These participants were divided into six age groups 
(20–29, 30–39, 40–49, 50–59, 60–69, and ≥70 years). IGF-I 
was measured by Liaison XL. This study was approved by the 
Institutional Review Board of Severance Hospital (IRB No. 
4-2018-1065). Written informed consent by the patients was 
waived due to a retrospective nature of our study.
After measuring IGF-I, Tukey method to remove outliers (eight 
men and 16 women) [7] and Anderson-Darling test to analyze 
the normality were applied. The skewed distributions of IGF-I 
in men aged 30 to 39 and 40 to 49 years were normalized using 
logarithmic transformation. Then we established the reference 
intervals using a parametric method, known to be most power-
ful when a random sample is obtained from a normally distrib-
uted population [8].
IGF-I value from each subject was classified into low, normal, 
and high based on the following: (1) reference intervals provid-
ed by the manufacturer; (2) those obtained in a previous study 
to allow standard deviation score (SDS) calculation; and (3) 
those derived in this study. To obtain the SDS, we used a calcu-
lator available online (http://ticemed_sa.upmc.fr/sd_score/) [9]. 
The categories are as followings: high (SDS >1.96), normal 
(SDS between −1.96 and 1.96), and low (SDS <−1.96). The 
agreement of classification among three reference intervals, ex-
pressed as weighted kappa and percentage of observed agree-
ment, was evaluated.
All statistical analyses were performed using Microsoft Excel 
2010 (Microsoft Corporation, Redmond, WA, USA), Analyse-it 
for Microsoft Excel Method Evaluation Edition version e.76.1 
(Analyse-it Software Ltd., Leeds, UK), and psych package of R 
software version 3.6.1 (R Core Team, 2019; R: A language and 
environment for statistical computing; R Foundation for Statis-
tical Computing; http://www.r-project.org). To interpret the kap-
pa values, Landis and Koch’s Table was used [10].
 
Table 1. Reference Intervals (90% CI) for IGF-I Based on Age Range and Sex in Study Subjects
Age group, yr No. Mean SD
Reference intervals for IGF-I, ng/mL
Lower limit (90% CI) Upper limit (90% CI)
Men
   20–29 147 262.79 68.09 127.77 (111.98–143.55) 397.81 (382.03–413.60)
   30–39 130 224.36 54.73 132.13 (124.19–140.57) 358.53 (336.99–381.44)
   40–49 124 199.15 52.78 110.09 (102.58–118.14) 334.69 (311.87–359.18)
   50–59 137 185.94 55.20 76.38 (63.12–89.64) 295.50 (282.24–308.76)
   60–69   78 166.06 47.82 72.03 (56.81–87.25) 260.09 (244.87–275.31)
   ≥70   64 137.33 41.74 55.19 (40.52–69.86) 219.47 (204.80–234.13)
Women
   20–29 124 256.99 71.70 114.50 (96.40–132.60) 399.49 (381.39–417.59)
   30–39 119 222.41 53.37 116.28 (102.52–130.03) 328.54 (314.79–342.30)
   40–49 128 192.67 48.54 96.25 (84.19–108.31) 289.09 (277.03–301.15)
   50–59 135 160.19 48.49 63.94 (52.21–75.67) 256.45 (244.72–268.18)
   60–69   85 144.88 47.84 50.83 (36.24–65.42) 238.93(224.35–253.52)
   ≥70   63 117.57 44.98 29.05 (13.12–44.98) 206.09 (190.16–222.02)
IGF-I, insulin-like growth factor I; SD, standard deviation; CI, confidence interval.
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RESULTS
After excluding outliers, the final reference population comprised 
1,334 subjects (680 men and 654 women). There were 147, 130, 
124, 137, 78, and 64 men and 124, 119, 128, 135, 85, and 63 
women in the 20–29, 30–39, 40–49, 50–59, 60–69, and ≥70 
years age groups, respectively.
In every age group, lower mean concentration in women than 
in men is observed; however, it is statistically significant only 
after the age of 50, the postmenopausal states. The IGF-I refer-
ence intervals (Table 1) showed that the mean values and upper 
limits of reference intervals decreased with an increase in age, 
while the lower limit showed a similar trend except for the age 
groups 20 to 29 and 30 to 39 (in both men and women). The new 
reference intervals were significantly higher in the upper limit 
especially in the age groups below 60 years compared to the Li-
aison package insert (Fig. 1), and the difference was much high-
er in men than in women. 
IGF-I values were classified as low, normal, and high accord-
ing to the new reference intervals, package insert, and SDS. 
Based on the classification, the agreement between new IGF-I 
reference intervals and manufacturer’s reference intervals was 
low and moderate with a kappa coefficient of 0.17 and 0.41 in 
men and women, respectively. Further, the agreement between 
new IGF-I reference intervals and SDS was moderate with a 
kappa coefficient of 0.51 and 0.53 in men and women, respec-
tively (Supplemental Table S1).
DISCUSSION
Ethnicity and the type of assay method employed are important 
when measuring and interpreting the IGF-I levels. Compared to 
the mean concentration levels of IGF-I in this study, lower val-
ues were reported when measured with the immunoradiometric 
method except for the women aged below 30 (Supplemental 
Table S2) [4]. To overcome the interlaboratory variability in pa-
tient classification, SDS calculator was established [1,9]; how-
ever, we observed a moderate agreement between the new refer-
ence intervals and SDS in men (kappa, 0.51) and women (kap-
pa, 0.53). This unsatisfactory agreement could be related to eth-
nicity, as the reference intervals provided by the manufacturer 
and SDS calculator were established in Europe. Therefore, the 
new reference intervals derived herein may be used in hospitals 
using Liaison, especially while interpreting IGF-I values in 
Asian adults. Despite the moderate concordance with SDS, the 
SDS calculator could be helpful to get an idea regarding patient 
classification; however, as racial differences are expected, an 
additional multicenter study comparing IGF-I reference inter-
vals in Asian healthy population should be conducted.
The present study has several limitations. First, despite of 
strictly designed exclusion criteria for selecting patients with 
most likely not affecting the growth hormone/IGF-I system, the 
definition of “healthy” population in this study may not abso-
lutely reflect the consensus requirement of a well characterized 
cohort of healthy subjects [11]. For example, we might have not 
excluded all the subjects with possible endocrine disorder or 
chrnoic infective diseases. Second, it was difficult to collect the 
data about hypertension, or pregnancy or menopausal status, or 
time of blood sample was taken due to the retrospective study 
design. Generally, the patients who visited outpatient clinics in 
our institute were asked to have a blood testing after having de-
sirably overnight or at least 4 hours of fasting. Third, although 
the analysis of fasting glucose level between patients classified 
into the same IGF-1 group and those classified into different 
group showed no significant difference, we could not complete-
ly confirm that nutritional condition had no effect on the discor-
dant result due to lack of body mass index information. Fourth, 
Fig. 1. Individual data and comparison between the new reference 
intervals and reference intervals of Liaison insert. The black points 
indicate individual data. New reference intervals are shown in col-
ored section (A: blue, men; B: red, women). Reference intervals of 
Liaison insert paper are shown in the grey section. Liaison insert 
paper only showed reference intervals until the age of 85 years. 
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although we excluded the subjects using estrogens, we could 
not have information for the use of other steroids [12,13]. Final-
ly, this study was conducted in one center in urban area, there-
fore multicenter study to confirm the reference intervals of IGF-
I should be needed. 
Despite these limitations, it should be noted that we enrolled 
at least 120 apparently healthy subjects based on strict exclusion 
criteria in group except the age over 60 years. As the kidney and 
liver functions and diabetic status may affect the level of IGF-I 
[14,15], we thoroughly examined patient medical history, liver 
profile, creatinine, and glucose levels. To our knowledge, this is 
the first study to establish IGF-I reference intervals measured 
with a chemiluminescence method in Korean population using 
an adequate number of reference subjects. 
In conclusion, we have established reference intervals for 
IGF-I measured by Liaison XL. As various factors affect the 
levels of IGF-I, reference intervals should be established based 
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